Annals of Palliative Medicine · 2021 · 13 citations · 28 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyRadiobiologyBiological Effects Of RadiationCellular Radiation ResponseManagement Of Acute Radiation ReactionsRadiation TherapyRadiation ToxicityTissue Responses To RadiationAcute Radiation InjuryRadiation Dose EffectsRadiation-induced Brain InjuryTissue Radiation InjuryVascular Endothelial Growth FactorVascular Endothelial Growth Factor Receptor SignalingVascular Endothelial Growth Factor ReceptorsVascular Endothelial Growth Factor Signaling
BACKGROUND: With the development of radiological technologies, radiotherapy has been gradually widely used in the clinic to intracranial tumours and become standardised. However, the related central nervous system disorders are still the most obvious complications after radiotherapy. This study aims to quantify the effectiveness of anlotinib, a small molecule inhibitor of multiple receptor tyrosine kinases, in mitigating acute phase of radiation-induced brain injury (RBI) in a mouse model. METHODS: The onset and progression of RBI were investigated in vivo. All mice, (except for the sham group) were irradiated at a single-fraction of 20 Gy and treated with different doses of anlotinib (0, 0.2 and 0.8 mg/kg, respectively). The expression levels of glial fibrillary acidic protein (GFAP), hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF), and phosphorylated vascular endothelial growth factor receptor-2 (p-VEGFR2) were assessed by western blot. Histological changes were identified by luxol fast blue (LFB) staining. RESULTS: The expression levels of GFAP, HIF-1α, and VEGF were downregulated following treatment with anlotinib. However, anlotinib failed to inhibit the development of demyelination. Cerebral edema [as measured by brain water content (BWC)] was also mitigated following treatment with anlotinib. CONCLUSIONS: In summary, treatment with anlotinib significantly mitigated the adverse effects of acute RBI in a dose-dependent manner by downregulating the activation of astrocytes, improving brain hypoxia, and alleviating cerebral edema.
28
Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?
Robert S. Kerbel · Science · 2006 · 470 citations
Medicine, Oncology, Pharmacology +17